These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9886326)

  • 1. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.
    Schröder JK; Kirch C; Seeber S; Schütte J
    Br J Haematol; 1998 Dec; 103(4):1096-103. PubMed ID: 9886326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential mechanisms of resistance to cytarabine in AML patients.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
    Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of cytidine deaminase mRNA in bone marrow cells from patients with acute leukemia].
    Sun ZQ; Jiang B; Zhao XS; Bao L; Wu T; Lu XJ; Kong Y; Wang DB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):246-50. PubMed ID: 12844405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Blood; 1997 Sep; 90(5):1968-76. PubMed ID: 9292531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C
    Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The assay of intracelluar cytidine deaminase activity and its clinical significance in patient with acute leukemia].
    Zhao XS; Sun Zq; Jiang B; Wang de B
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Apr; 40(2):181-4. PubMed ID: 18458696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
    Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
    Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.
    Kirch HC; Schröder J; Hoppe H; Esche H; Seeber S; Schütte J
    Exp Hematol; 1998 May; 26(5):421-5. PubMed ID: 9590659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
    Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
    Br J Haematol; 2001 Jun; 113(4):975-82. PubMed ID: 11442492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
    Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
    Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
    Veuger MJ; Honders MW; Willemze R; Barge RM
    Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
    Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
    Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.
    Schaich M; Ritter M; Illmer T; Lisske P; Thiede C; Schäkel U; Mohr B; Ehninger G; Neubauer A
    Br J Haematol; 2001 Feb; 112(2):300-7. PubMed ID: 11167822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).
    Brennig S; Lachmann N; Buchegger T; Hetzel M; Schambach A; Moritz T
    J Exp Clin Cancer Res; 2015 Dec; 34():148. PubMed ID: 26651614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.
    Hyo Kim L; Sub Cheong H; Koh Y; Ahn KS; Lee C; Kim HL; Doo Shin H; Yoon SS
    J Hum Genet; 2015 Dec; 60(12):749-54. PubMed ID: 26354033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.